Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

VSL#3 / Visbiome

The High-Potency Multi-Strain With Real Evidence

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

5 human trials, about 60 studies, Thousands. The written rationale for this grade is still being prepared.

FDA
Medical food; the formula's history is contested
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

In the trials the formulation was generally well tolerated; mild bloating or gas is the most commonly reported effect, and can be more noticeable at the high doses used clinically. As with all live multi-strain products, caution is warranted in severely immunocompromised patients and those with central venous catheters or critical illness, where live-organism supplements have been associated with rare infection signals. Pouchitis and ulcerative colitis are serious conditions managed with prescription therapy, so decisions about starting, stopping, or substituting for medication should be made with a qualified gastroenterologist rather than self-directed. The distinct consumer caution here is identity: confirm the product carries the actually-studied De Simone Formulation (Visbiome or Vivomixx), since a US court found equivalence claims for the reformulated VSL#3 to be false.

The 'De Simone Formulation,' a high-potency eight-strain lactic-acid-bacteria blend delivering hundreds of billions of CFU per dose, carries some of the most indication-specific clinical evidence in the probiotic field, concentrated in pouchitis (inflammation of a surgically created ileal pouch in some ulcerative colitis patients after colectomy) and, more moderately, mild-to-moderate ulcerative colitis. It was sold as VSL#3 from roughly 2002 to 2016. After inventor Professor Claudio De Simone ended his relationship with the brand's owners, the original studied formulation moved to new brand names (Visbiome in the US and Canada, Vivomixx in Europe), made for ExeGi Pharma, while the VSL#3 name continued under a different Italian manufacturer. A US federal jury found the continuing VSL#3 sellers liable for falsely advertising their new product as equivalent to the studied formula, a completed legal action that makes this entry a clear object lesson: probiotic evidence attaches to a specific formulation, not to a logo.

A high-dose 8-strain probiotic with genuine evidence for pouchitis, and a cautionary tale about formula identity and branding.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Maintaining remission of chronic and recurrent/refractory pouchitis (strongest, multi-RCT evidence)
  • Preventing onset of pouchitis after ileal pouch-anal anastomosis (prophylaxis; RCT-supported)
  • Adjunct alongside standard therapy in mild-to-moderate ulcerative colitis (moderate RCT support)
  • Reference case for high-CFU multi-strain clinical use
  • Teaching example for formulation-versus-brand identity in probiotics

What people get wrong

  • Often saidThe brand name on the box guarantees you are getting the studied product

    ActuallyNot necessarily, and this is the entry's central documented lesson. The formulation studied in the pouchitis and ulcerative colitis trials was sold as VSL#3 until about 2016, then moved to Visbiome and Vivomixx. A US federal jury (2018) and the Fourth Circuit (2021) found the continuing VSL#3 sellers liable for falsely advertising their reformulated product as equivalent to the studied one. The brand and the studied formula can diverge.

  • Often saidMore strains and higher CFU are automatically better

    ActuallyHigh CFU and the specific eight-strain composition matter for this product's pouchitis evidence, but that is a finding about this formulation, not a general law. Benefit remains strain-, formulation-, and disease-specific; a different high-count multi-strain product does not inherit these trial results.

  • Often saidThe strong pouchitis evidence means the product is proven for general 'gut health' or IBS

    ActuallyNo. The ev=4 rating is associated specifically with pouchitis (strongest) and mild-to-moderate ulcerative colitis (moderate, as an adjunct). Extending that to routine digestive wellness, IBS, or immunity is not supported by the anchoring RCTs and should be treated as a much lower-evidence use.

Who profits, and who pushes back

  • Visbiome (ExeGi Pharma)

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itCurrent formulation maker

    Markets the original studied De Simone formulation; the pouchitis evidence is genuine, but the branding history is contested commercial territory.

  • VSL#3 (Alfasigma)

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itOriginal brand

    Continued the VSL#3 name after the formulation dispute; whether later VSL#3 matches the trial formula has been litigated and debated.

  • IBD/pouchitis researchers

    Promotes itClinical trials

    Provide the strong pouchitis evidence for the high-potency De Simone formulation.

  • American Gastroenterological Association (AGA) pouchitis guideline panel

    Pushes backAuthors of the 2024 AGA Clinical Practice Guideline on management of pouchitis and inflammatory pouch disorders

    The guideline suggests the De Simone Formulation to prevent recurrent pouchitis, but frames the recommendation as conditional, signaling genuine but not definitive certainty.

  • Professor Claudio De Simone

    Pushes backInventor of the formulation; plaintiff in the successful false-advertising case

    De Simone's position, upheld by the court, was that the reformulated VSL#3 was 'untested' and could not claim the clinical results of the original formulation, which he argues moved with him to Visbiome/Vivomixx.

  • Proskauer Rose LLP (Lanham Act commentators)

    Pushes backLitigation analysts summarizing the verdict

    Their analysis characterizes the case as a 15 million dollar false-advertising judgment turning on marketing a reformulated probiotic as identical to the originally studied one without supporting clinical data.

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
USA40%
Europe35%
Other25%

Research published from: USA, Italy, Global.

How we got here

The formulation originates with the Italian gastroenterology research tradition. Professor Claudio De Simone designed the eight-strain, high-CFU blend, and the University of Bologna group led by Paolo Gionchetti and Massimo Campieri produced its foundational pouchitis trials starting in 2000. This is a European scientific origin story that is accurate rather than a default: the anchoring randomized trials were run in Bologna, Italy, and the product was initially manufactured at a US facility for the VSL#3 brand between about 2002 and 2016. The clinical program deliberately targeted a niche where conventional therapy is thin, recurrent and antibiotic-refractory pouchitis, and later extended to ulcerative colitis. When De Simone ended his relationship with the VSL#3 owners, the original formulation was re-launched under Visbiome for ExeGi Pharma in the US and Canada and Vivomixx in Europe, while the VSL#3 trademark continued under separate Italian production. That split turned a probiotic into a landmark case study of formulation identity versus brand name.

  1. 2000Gionchetti et al. publish the first double-blind placebo-controlled RCT of the formulation (as VSL#3) for maintaining remission of chronic pouchitis in Gastroenterology
  2. 2002Formulation begins commercial sale under the VSL#3 brand
  3. 2003Gionchetti et al. publish a second RCT showing the formulation prevents onset (prophylaxis) of pouchitis after ileal pouch surgery
  4. 2004Mimura et al. confirm maintenance of remission in recurrent/refractory pouchitis (85% vs 6% at one year) in Gut, replicating the pouchitis signal independently
  5. 2009-2010Sood and Tursi multicenter RCTs report benefit in mild-to-moderate ulcerative colitis, extending the evidence base beyond pouchitis
  6. 2016The studied formulation departs the VSL#3 brand; it is re-launched as Visbiome (US/Canada) and Vivomixx (Europe) for ExeGi Pharma, while the VSL#3 name continues under a different Italian manufacturer
  7. 2018A Maryland federal jury finds the continuing VSL#3 sellers liable for false advertising under the Lanham Act, awarding De Simone and ExeGi more than 18 million dollars, of which 15 million was for false advertising
  8. 2021The US Court of Appeals for the Fourth Circuit affirms the 15 million false-advertising verdict and the injunction against claiming continuity with the original formulation
  9. 2024The AGA Clinical Practice Guideline on pouchitis names the De Simone Formulation with a conditional recommendation for preventing recurrent pouchitis

At a glance

Strains
8-strain high-CFU blend
Best evidence
Pouchitis prevention/maintenance
CFU
Very high (hundreds of billions)
Note
Original formula now sold as Visbiome

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about VSL#3 / Visbiome. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources